Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 103

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Consensus on acromegaly therapeutic outcomes: an update

Melmed, Shlomo, di Filippo, Luigi, Fleseriu, Maria, Mercado, Moisés, Karavitaki, Niki, Gurnell, Mark, Salvatori, Roberto, Tsagarakis, Stylianos, Losa, Marco, Maffei, Pietro, Pereira, Alberto M., Geer, Eliza B., Katznelson, Laurence, van der Lely, Aart Jan, Bollerslev, Jens, Esposito, Daniela, Webb, Susan M., Zatelli, Maria Chiara, Valassi, Elena, Neggers, Sebastian, Chanson, Philippe, Ho, Ken K. Y., Ioachimescu, Adriana G., Biller, Beverly M. K., Samson, Susan L., Kaiser, Ursula B., Schilbach, Katharina, Luque, Raúl M., Casanueva, Felipe F., Shimon, Ilan, Boguszewski, Cesar L., Biermasz, Nienke, Colao, Annamaria, Pirchio, Rosa, Lamberts, Steven W. J., Kadioglu, Pinar, Buchfelder, Michael, Frara, Stefano, Chiloiro, Sabrina, Petersenn, Stephan, Gadelha, Monica R., Puig-Domingo, Manel, Luger, Anton, Brue, Thierry, Beckers, Albert, Ferone, Diego, Clemmons, David R., Greenman, Yona, Marazuela, Mónica, Mortini, Pietro, Strasburger, Christian J., Giustina, Andrea·2025·Nature Reviews Endocrinology
DOI 10.1038/s41574-025-01148-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41574-025-01148-2

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 171

  1. Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V. & Melmed, S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10, 804–826 (2022). · DOI · Paper page
  2. Melmed, S. et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43, 1003–1037 (2022). · DOI · Paper page
  3. Colao, A. et al. Acromegaly. Nat. Rev. Dis. Prim. 5, 20 (2019). · DOI · Paper page
  4. Bolfi, F., Neves, A. F., Boguszewski, C. L. & Nunes-Nogueira, V. S. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur. J. Endocrinol. 179, 59–71 (2018). · DOI · Paper page
  5. Esposito, D. et al. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur. J. Endocrinol. 178, 459–469 (2018). · DOI
  6. Melmed, S. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16, 294–302 (2013). · DOI · Paper page
  7. Giustina, A. et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, dgz096 (2020). · DOI · Paper page
  8. Melmed, S. et al. A consensus statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14, 552–561 (2018). · DOI · Paper page
  9. Giustina, A. et al. Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21, 667–678 (2020). · DOI · Paper page
  10. Fleseriu, M. et al. A pituitary society update to acromegaly management guidelines. Pituitary 24, 1–13 (2021). · DOI · Paper page
  11. Katznelson, L. et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014). · DOI · Paper page
  12. Giustina, A. et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary 27, 7–22 (2024). · DOI · Paper page
  13. Swiglo, B. A. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 666–673 (2008). · DOI · Paper page
  14. Chiloiro, S. et al. Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25, 831–841 (2022). · DOI
  15. Cangiano, B. et al. Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life. Endocrine 77, 510–518 (2022). · DOI
  16. Frara, S. et al. High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J. Clin. Endocrinol. Metab. 107, e2843–e2850 (2022). · DOI
  17. Giustina, A. Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol. Metab. 31, 274–275 (2020). · DOI
  18. Giustina, A. Acromegaly and bone: an update. Endocrinol. Metab. 38, 655–666 (2023). · DOI
  19. Cardinal, T. et al. Postoperative GH and degree of reduction in IGF-1 predicts postoperative hormonal remission in acromegaly. Front. Endocrinol. 12, 743052 (2021). · DOI
  20. Feelders, R. A. et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J. Clin. Endocrinol. Metab. 90, 6480–6489 (2005). · DOI
  21. Wang, Y. Y. et al. Value of early post-operative growth hormone testing in predicting long-term remission and residual disease after transsphenoidal surgery for acromegaly. Neuroendocrinology 112, 345–357 (2022). · DOI
  22. Giustina, A., Mazziotti, G. & Fontanella, M. Commentary: postsurgical monitoring of acromegaly. Neurosurgery 73, E746–E748 (2013). · DOI
  23. Jung, I. H. et al. Revisiting the role of insulin-like growth factor-1 measurement after surgical treatment of acromegaly. J. Clin. Endocrinol. Metab. 106, e2589–e2599 (2021). · DOI
  24. Cunha, M. L. V. D., Borba, L. A. B. & Boguszewski, C. L. Random Gh and Igf-I levels after transsphenoidal surgery for acromegaly: relation with long-term remission. Endocrine 68, 182–191 (2020). · DOI
  25. Freda, P. U. et al. Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly. Pituitary 24, 170–183 (2021). · doi:10.1007/s11102-020-01094-4
  26. Giustina, A. et al. International multicenter validation study of the SAGIT® instrument in acromegaly. J. Clin. Endocrinol. Metab. 106, 3555–3568 (2021).
  27. Forghani, R. Adverse effects of gadolinium-based contrast agents: changes in practice patterns. Top. Magn. Reson. Imaging 25, 163–169 (2016). · doi:10.1097/rmr.0000000000000095
  28. Koulouri, O. et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur. J. Endocrinol. 175, 485–498 (2016). · DOI
  29. Bashari, W. A. et al. PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg. Focus 48, E8 (2020). · doi:10.3171/2020.3.focus2052
  30. Claessen, K. M., Mazziotti, G., Biermasz, N. R. & Giustina, A. Bone and joint disorders in acromegaly. Neuroendocrinology 103, 86–95 (2016). · DOI
  31. Martin, S. et al. Development and evaluation of the acromegaly symptom diary. J. Patient Rep. Outcomes 7, 15 (2023). · DOI
  32. Esposito, D. et al. Effect of diabetes on morbidity and mortality in patients with acromegaly. J. Clin. Endocrinol. Metab. 107, 2483–2492 (2022). · DOI
  33. Yen, Y. S. & Chen, H. S. Changes in cardiovascular risk factors in patients with acromegaly after trans-sphenoidal adenomectomy. Endocr. J. 67, 1169–1177 (2020). · doi:10.1507/endocrj.ej20-0159
  34. Kong, X., Gong, S., Su, L., Howard, N. & Kong, Y. Automatic detection of acromegaly from facial photographs using machine learning methods. eBioMedicine 27, 94–102 (2018). · DOI
  35. Meng, T. et al. Identifying facial features and predicting patients of acromegaly using three-dimensional imaging techniques and machine learning. Front. Endocrinol. 11, 492 (2020). · doi:10.3389/fendo.2020.00492
  36. Wang, M. et al. Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach. Quant. Imaging Med. Surg. 13, 3747–3759 (2023). · doi:10.21037/qims-22-1101
  37. Casanueva, F. F. et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary 20, 489–498 (2017). · DOI · Paper page
  38. Giustina, A. et al. Pilot study to define criteria for pituitary tumors centers of excellence (PTCOE): results of an audit of leading international centers. Pituitary 26, 583–596 (2023). · DOI
  39. Gadelha, M. R. et al. Pituitary MRI standard and advanced sequences: role in the diagnosis and characterization of pituitary adenomas. J. Clin. Endocrinol. Metab. 107, 1431–1440 (2022). · doi:10.1210/clinem/dgab901
  40. Micko, A. S., Wöhrer, A., Wolfsberger, S. & Knosp, E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J. Neurosurg. 122, 803–811 (2015). · DOI · Paper page
  41. Heck, A., Emblem, K. E., Casar-Borota, O., Bollerslev, J. & Ringstad, G. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52, 333–343 (2016). · doi:10.1007/s12020-015-0766-8
  42. Potorac, I., Beckers, A. & Bonneville, J. F. T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. Pituitary 20, 116–120 (2017). · doi:10.1007/s11102-017-0788-8
  43. Ruiz, S. et al. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin. Endocrinol. 99, 378–385 (2023). · DOI
  44. Puig-Domingo, M. et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J. Clin. Endocrinol. Metab. 95, 4973–4978 (2010). · doi:10.1210/jc.2010-0573
  45. Bonneville, F. et al. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. Eur. J. Endocrinol. 180, 155–164 (2018). · doi:10.1530/eje-18-0254
  46. Coopmans, E. C. et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur. J. Endocrinol. 182, 595–605 (2020). · DOI
  47. Kocak, B. et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur. Radiol. 29, 2731–2739 (2019). · DOI
  48. Park, Y. W. et al. Radiomics model predicts granulation pattern in growth hormone-secreting pituitary adenomas. Pituitary 23, 691–700 (2020). · DOI
  49. Bashari, W. A. et al. Using molecular imaging to enhance decision making in the management of pituitary adenomas. J. Nucl. Med. 62, 57S–62S (2021). · DOI
  50. Wildemberg, L. E. et al. Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. J. Clin. Endocrinol. Metab. 106, 2047–2056 (2021). · DOI
  51. Hu, J. et al. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas. J. Endocrinol. Invest. 42, 443–451 (2019). · doi:10.1007/s40618-018-0939-4
  52. Berton, A. M. et al. Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study. J. Clin. Med. 12, 25 (2022). · doi:10.3390/jcm12010025
  53. Ilie, M. D. et al. Predictive factors of somatostatin receptor ligand response in acromegaly — a prospective study. J. Clin. Endocrinol. Metab. 107, 2982–2991 (2022). · doi:10.1210/clinem/dgac512
  54. Oriola, J. et al. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur. J. Endocrinol. 168, 9–13 (2012). · doi:10.1530/eje-12-0457
  55. Daly, A. F. et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metab. 95, E373–E383 (2010). · DOI · Paper page
  56. Beckers, A. et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr. Relat. Cancer 22, 353–367 (2015). · DOI · Paper page
  57. Wildemberg, L. E. et al. gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly. Cancers 13, 4857 (2021). · doi:10.3390/cancers13194857
  58. Puig-Domingo, M. et al. Molecular profiling for acromegaly treatment: a validation study. Endocr. Relat. Cancer 27, 375–389 (2020). · doi:10.1530/erc-18-0565
  59. Iacovazzo, D. et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur. J. Endocrinol. 174, 241–250 (2016). · doi:10.1530/eje-15-0832
  60. Chiloiro, S. et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184, 217–229 (2021). · doi:10.1530/eje-20-0767
  61. Muhammad, A. et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J. Clin. Endocrinol. Metab. 104, 915–924 (2019). · doi:10.1210/jc.2018-01524
  62. Cuevas-Ramos, D. et al. A structural and functional acromegaly classification. J. Clin. Endocrinol. Metab. 100, 122–131 (2015). · DOI
  63. Coopmans, E. C. et al. Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J. Clin. Endocrinol. Metab. 105, dgaa387 (2020). · doi:10.1210/clinem/dgaa387
  64. Sulu, C. et al. Machine learning as a clinical decision support tool for patients with acromegaly. Pituitary 25, 486–495 (2022). · DOI
  65. Caron, P. J. et al. Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J. Clin. Endocrinol. Metab. 99, 1282–1290 (2014). · DOI · Paper page
  66. Biagetti, B. et al. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Front. Endocrinol. 13, 984877 (2022). · doi:10.3389/fendo.2022.984877
  67. Urai, S. et al. Newer parameters of the octreotide test in patients with acromegaly. Pituitary 27, 33–43 (2024). · doi:10.1007/s11102-023-01362-z
  68. Bidlingmaier, M. et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J. Clin. Endocrinol. Metab. 99, 1712–1721 (2014). · DOI · Paper page
  69. Chanson, P. et al. Reference values for IGF-I serum concentrations: comparison of six immunoassays. J. Clin. Endocrinol. Metab. 101, 3450–3458 (2016). · DOI
  70. Gola, M., Bonadonna, S., Mazziotti, G., Amato, G. & Giustina, A. Resistance to somatostatin analogs in acromegaly: an evolving concept? J. Endocrinol. Invest. 29, 86–93 (2006). · DOI
  71. Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189–3202 (2009). · DOI · Paper page
  72. Gadelha, M. R., Kasuki, L., Lim, D. S. T. & Fleseriu, M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019). · DOI · Paper page
  73. Petrossians, P. et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) database. Endocr. Relat. Cancer 24, 505–518 (2017). · DOI · Paper page
  74. Kyriakakis, N., Lynch, J., Gilbey, S. G., Webb, S. M. & Murray, R. D. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin. Endocrinol. 86, 806–815 (2017). · DOI
  75. van Trigt, V. R., Pelsma, I. C. M. & Biermasz, N. R. Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need. Pituitary 26, 307–317 (2023). · DOI
  76. Maione, L. et al. IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands. J. Clin. Endocrinol. Metab. 107, e3644–e3653 (2022). · doi:10.1210/clinem/dgac385
  77. Marques, N. V., Wildemberg, L. E. A. & Gadelha, M. R. Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly. Endocr. Connect. 12, e230155 (2023). · doi:10.1530/ec-23-0155
  78. Colao, A., Auriemma, R. S., Pivonello, R., Kasuki, L. & Gadelha, M. R. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19, 235–247 (2016). · doi:10.1007/s11102-015-0684-z
  79. Carmichael, J. D., Bonert, V. S., Nuño, M., Ly, D. & Melmed, S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 1825–1833 (2014). · DOI · Paper page
  80. Giustina, A. et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102, 2454–2464 (2017). · DOI
  81. Giustina, A. et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161, 331–338 (2009). · DOI
  82. Samson, S. L. et al. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J. Clin. Endocrinol. Metab. 105, e3785–e3797 (2020). · doi:10.1210/clinem/dgaa526
  83. Fleseriu, M. et al. MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly. J. Clin. Endocrinol. Metab. 108, 3214–3222 (2023). · DOI
  84. Gadelha, M. R. et al. ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J. Clin. Endocrinol. Metab. 108, e148–e159 (2023). · doi:10.1210/clinem/dgac643
  85. Colao, A. et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014). · DOI · Paper page
  86. Gadelha, M. et al. Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front. Endocrinol. 10, 931 (2020). · DOI
  87. Gadelha, M. R. et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2, 875–884 (2014). · DOI · Paper page
  88. Colao, A. et al. Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study. Eur. J. Endocrinol. 182, 583 (2020). · doi:10.1530/eje-19-0762
  89. Colao, A., Auriemma, R. S. & Pivonello, R. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary 19, 210–221 (2016). · DOI
  90. Giustina, A. et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7, e36411 (2012). · DOI · Paper page
  91. Benderradji, H. et al. Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month. Clin. Endocrinol. 97, 52–63 (2022). · doi:10.1111/cen.14748
  92. Mondin, A. et al. Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front. Endocrinol. 13, 935759 (2022). · DOI
  93. Grandgeorge, N., Barchetti, G., Grunenwald, S., Bonneville, F. & Caron, P. Is MRI follow-up relevant in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogues (SMSa)? Eur. J. Endocrinol. 182, 123–130 (2020). · doi:10.1530/eje-19-0681
  94. Gadelha, M. R., Wildemberg, L. E. & Kasuki, L. The future of somatostatin receptor ligands in acromegaly. J. Clin. Endocrinol. Metab. 107, 297–308 (2022). · doi:10.1210/clinem/dgab726
  95. Wolters, T. L. C. et al. The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur. J. Endocrinol. 182, 319–331 (2020). · doi:10.1530/eje-19-0732
  96. Giustina, A. et al. Sagit©: a novel clinician-reported outcome for managing acromegaly in clinical practice. Value Health 17, A355 (2014). · doi:10.1016/j.jval.2014.08.754
  97. Giustina, A. et al. SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice — development and results from a pilot study. Pituitary 19, 39–49 (2016). · doi:10.1007/s11102-015-0681-2
  98. Giustina, A. et al. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary 22, 476–487 (2019). · doi:10.1007/s11102-019-00977-5
  99. Marazuela, M. et al. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study. Endocrine 75, 525–536 (2022). · doi:10.1007/s12020-021-02900-0
  100. van der Meulen, M. et al. State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 107, 1225–1238 (2022). · DOI
  101. Geer, E. B. et al. Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice. BMC Endocr. Disord. 20, 117 (2020).
  102. Fleseriu, M. et al. Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front. Endocrinol. 12, 627711 (2021).
  103. Prencipe, N. et al. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. Pituitary 24, 242–251 (2021). · DOI
  104. Burness, C. B., Dhillon, S. & Keam, S. J. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly. Drugs 74, 1673–1691 (2014). · doi:10.1007/s40265-014-0283-8
  105. Bornschein, J., Drozdov, I. & Malfertheiner, P. Octreotide LAR: safety and tolerability issues. Expert Opin. Drug Saf. 8, 755–768 (2009). · DOI
  106. Frara, S., Maffezzoni, F., Mazziotti, G. & Giustina, A. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470–483 (2016). · DOI
  107. Mazziotti, G. et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500–1508 (2009). · DOI · Paper page
  108. Cozzolino, A. et al. Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J. Clin. Endocrinol. Metab. 103, 2089–2099 (2018). · DOI
  109. Bolanowski, M., Kałużny, M., Witek, P. & Jawiarczyk-Przybyłowska, A. Pasireotide — a novel somatostatin receptor ligand after 20 years of use. Rev. Endocr. Metab. Disord. 23, 601–620 (2022). · DOI
  110. Barbot, M. et al. Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary 23, 534–542 (2020). · DOI
  111. Henry, R. R. et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 98, 3446–3453 (2013). · DOI · Paper page
  112. Gadelha, M. et al. Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience. J. Clin. Endocrinol. Metab. 108, e1571–e1579 (2023). · DOI
  113. Samson, S. L. et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary 24, 887–903 (2021). · DOI
  114. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. & Kuhn, J. M. Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly. Clin. Endocrinol. 64, 209–214 (2006). · doi:10.1111/j.1365-2265.2006.02450.x
  115. Parolin, M., Dassie, F., Vettor, R., Steeds, R. P. & Maffei, P. Electrophysiological features in acromegaly: re-thinking the arrhythmic risk? J. Endocrinol. Invest. 44, 209–221 (2021). · DOI
  116. Giustina, A. et al. Pegvisomant in acromegaly: an update. J. Endocrinol. Invest. 40, 577–589 (2017). · DOI
  117. Trainer, P. J. et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000). · DOI · Paper page
  118. Haberbosch, L. & Strasburger, C. J. Efficacy and safety of pegvisomant in the treatment of acromegaly. Arch. Med. Res. 54, 102884 (2023). · doi:10.1016/j.arcmed.2023.102884
  119. Fleseriu, M. et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur. J. Endocrinol. 185, 525–538 (2021). · DOI
  120. Pirchio, R. et al. Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience. J. Endocrinol. Invest. 46, 1027–1038 (2023). · DOI
  121. Droste, M. et al. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels. Eur. J. Endocrinol. 171, 59–68 (2014). · DOI
  122. Buchfelder, M. et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur. J. Endocrinol. 179, 419–427 (2018). · doi:10.1530/eje-18-0616
  123. Leonart, L. P., Tonin, F. S., Ferreira, V. L., Fernandez-Llimos, F. & Pontarolo, R. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63, 18–26 (2019). · doi:10.1007/s12020-018-1729-7
  124. Brue, T. et al. Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine 63, 563–572 (2019). · doi:10.1007/s12020-018-1792-0
  125. Chiloiro, S. et al. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J. Clin. Endocrinol. Metab. 105, dgz054 (2020). · DOI
  126. Salvatori, R. et al. Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience. Pituitary 25, 420–432 (2022). · doi:10.1007/s11102-022-01206-2
  127. Feola, T. et al. Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J. Clin. Endocrinol. Metab. 104, 2892–2902 (2019). · doi:10.1210/jc.2018-02281
  128. Sesmilo, G. et al. Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study. Clin. Endocrinol. 81, 883–890 (2014). · doi:10.1111/cen.12440
  129. Ma, L. et al. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies. BMC Endocr. Disord. 20, 126 (2020).
  130. Neggers, S. J. et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93, 3853–3859 (2008). · DOI · Paper page
  131. Madsen, M., Poulsen, P. L., Orskov, H., Møller, N. & Jørgensen, J. O. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J. Clin. Endocrinol. Metab. 96, 2405–2413 (2011). · DOI
  132. van der Lely, A. J. et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol. 164, 325–333 (2011). · doi:10.1530/eje-10-0867
  133. Giustina, A. et al. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary 27, 381–388 (2024). · DOI
  134. Neggers, S. J. et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab. 99, 3644–3652 (2014). · doi:10.1210/jc.2014-2032
  135. Bonert, V. et al. Cost–effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J. Clin. Endocrinol. Metab. 105, dgaa444 (2020). · DOI
  136. Muhammad, A. et al. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur. J. Endocrinol. 179, 269–277 (2018). · doi:10.1530/eje-18-0353
  137. Auriemma, R. S. et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55, 872–884 (2017). · DOI
  138. Sandret, L., Maison, P. & Chanson, P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 1327–1335 (2011). · DOI · Paper page
  139. Bernabeu, I. et al. Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16, 101–108 (2013). · DOI
  140. Higham, C. E. et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J. Clin. Endocrinol. Metab. 97, 1187–1193 (2012). · DOI
  141. Strasburger, C. J. et al. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. Eur. J. Endocrinol. 178, 321–329 (2018). · doi:10.1530/eje-17-0996
  142. Chiloiro, S. et al. Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study. J. Clin. Endocrinol. Metab. 104, 5478–5482 (2019). · doi:10.1210/jc.2019-00825
  143. Muhammad, A. et al. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J. Clin. Endocrinol. Metab. 103, 586–595 (2018). · doi:10.1210/jc.2017-02017
  144. Chiloiro, S. et al. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus pegvisomant. Endocrine 73, 658–666 (2021). · DOI
  145. Guo, X. et al. Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients. J. Neurosurg. 137, 618–628 (2022). · DOI
  146. Mohyeldin, A. et al. Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission outcomes. Sci. Rep. 12, 9919 (2022). · DOI
  147. Albarel, F. et al. Preoperative medical treatment for patients with acromegaly: yes or no? J. Endocr. Soc. 6, bvac114 (2022). · doi:10.1210/jendso/bvac114
  148. Pita-Gutierrez, F. et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS ONE 8, e61523 (2013). · doi:10.1371/journal.pone.0061523
  149. Jacob, J. J. & Bevan, J. S. Should all patients with acromegaly receive somatostatin analogue therapy before surgery and, if so, for how long? Clin. Endocrinol. 81, 812–817 (2014). · doi:10.1111/cen.12553
  150. Nunes, V. S., Correa, J. M., Puga, M. E., Silva, E. M. & Boguszewski, C. L. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system. Pituitary 18, 500–508 (2015). · DOI
  151. Albarel, F. et al. Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. Pituitary 21, 615–623 (2018). · DOI
  152. Melmed, S. et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J. Clin. Endocrinol. Metab. 100, 1699–1708 (2015). · DOI · Paper page
  153. Fleseriu, M. et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 10, 102–111 (2022). · DOI
  154. Pavel, M. et al. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. Cancer Chemother. Pharmacol. 83, 375–385 (2019). · DOI
  155. Giustina, A. et al. Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. Endocrine 71, 273–280 (2021). · DOI
  156. Frara, S. et al. COVID-19 and the pituitary. Pituitary 24, 465–481 (2021). · DOI
  157. Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937–950 (2020). · DOI · Paper page
  158. Urwyler, S. A. et al. Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-centre cohort study. Eur. J. Endocrinol. 190, 113–120 (2024). · doi:10.1093/ejendo/lvae003
  159. Auriemma, R. S., Pivonello, R., Ferreri, L., Priscitelli, P. & Colao, A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol. Metab. Clin. North Am. 44, 89–97 (2015). · DOI
  160. Stiles, C. E., Tetteh-Wayoe, E. T., Bestwick, J., Steeds, R. P. & Drake, W. M. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J. Clin. Endocrinol. Metab. 104, 523–538 (2019). · DOI
  161. Hamidianjahromi, A. & Tritos, N. A. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev. Endocr. Metab. Disord. 23, 1089–1099 (2022).
  162. Giustina, A., Boni, E., Romanelli, G., Grassi, V. & Giustina, G. Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am. J. Cardiol. 75, 1042–1047 (1995). · DOI
  163. van der Lely, A. J. et al. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly. Eur. J. Endocrinol. 182, D17–D29 (2020). · doi:10.1530/eje-19-0998
  164. Giustina, A., di Filippo, L., Uygur, M. M. & Frara, S. Modern approach to resistant acromegaly. Endocrine 80, 303–307 (2023). · DOI
  165. Coopmans, E. C., van der Lely, A. J. & Neggers, S. J. C. M. M. Approach to the patient with treatment-resistant acromegaly. J. Clin. Endocrinol. Metab. 107, 1759–1766 (2022). · doi:10.1210/clinem/dgac037
  166. Stone, J. C., Clark, J., Cuneo, R., Russell, A. W. & Doi, S. A. Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary 17, 284–295 (2014). · DOI
  167. Duarte, F. H., Jallad, R. S. & Bronstein, M. D. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J. Clin. Endocrinol. Metab. 100, 1863–1869 (2015). · DOI
  168. Magalhães, J. et al. A prospective study on the efficacy of oral estrogen in female patients with acromegaly. Pituitary 25, 433–443 (2022). · DOI
  169. Ho, K. K. Y. et al. A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement. Pituitary 22, 569–573 (2019). · DOI
  170. Whitelaw, B. C. How and when to use temozolomide to treat aggressive pituitary tumours. Endocr. Relat. Cancer 26, R545–R552 (2019). · DOI
  171. Ho, K. K. Y. et al. A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis. Lancet Diabetes Endocrinol. 12, 209–214 (2024). · DOI

Metadata

Authors
Melmed, S., di Filippo, L., Fleseriu, M., Mercado, M., Karavitaki, N., Gurnell, M., Salvatori, R., Tsagarakis, S., Losa, M., Maffei, P., Pereira, A. M., Geer, E. B., Katznelson, L., van der Lely, A. J., Bollerslev, J., Esposito, D., Webb, S. M., Zatelli, M. C., Valassi, E., Neggers, S., Chanson, P., Ho, K. K. Y., Ioachimescu, A. G., Biller, B. M. K., Samson, S. L., Kaiser, U. B., Schilbach, K., Luque, R. M., Casanueva, F. F., Shimon, I., Boguszewski, C. L., Biermasz, N., Colao, A., Pirchio, R., Lamberts, S. W. J., Kadioglu, P., Buchfelder, M., Frara, S., Chiloiro, S., Petersenn, S., Gadelha, M. R., Puig-Domingo, M., Luger, A., Brue, T., Beckers, A., Ferone, D., Clemmons, D. R., Greenman, Y., Marazuela, M., Mortini, P., Strasburger, C. J., & Giustina, A.
Venue
Nature Reviews Endocrinology
Publisher
Springer Science and Business Media LLC
Published
2025-08-13
Volume
21
Issue
11
Pages
718-737
ISSN
  • 1759-5029
  • 1759-5037
DOI
10.1038/s41574-025-01148-2
Cited by
103
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Consensus on acromegaly therapeutic outcomes: an update. https://app.cochat.ai/papers/10.1038/s41574-025-01148-2
The paper
Melmed, S., di Filippo, L., Fleseriu, M., Mercado, M., Karavitaki, N., Gurnell, M., Salvatori, R., Tsagarakis, S., Losa, M., Maffei, P., Pereira, A. M., Geer, E. B., Katznelson, L., van der Lely, A. J., Bollerslev, J., Esposito, D., Webb, S. M., Zatelli, M. C., Valassi, E., . . . Giustina, A. (2025). Consensus on acromegaly therapeutic outcomes: an update. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-025-01148-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.